SZU General Hospital

Xiangwei Wang
SZU General Hospital
Urology
Professor
简介:


BIOGRAPHICAL SKETCH


NAME: Xiangwei Wang


POSITION TITLE: Director of Urology, Shenzhen University General Hospital; Visiting Professor of Georgia Medical University, USA


EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

COMLETION DATE

FIELD OF STUDY

Taishan Medical College

Bachelor

1993

Clinical medicine

Third Military Medical University,Chongqing

MD

1998

Urology

Third Military Medical University,Chongqing

Ph.D

2002

Urology

 

 

 

 

 

 

 

 

 

A. Personal statement

Wang Xiangwei, born in 1969, obtained a Ph.D. degree from the Third Military Medical University and entered the post-doctoral research station of Peking University Institute of Urology (cooperative tutor: Academician Guo Yinglu), engaged in the research of urologic tumor vaccines, drug resistance and targeted puncture robots. He has published >80 papers (including SCI and domestic papers) in journals such as Cell Metabolism (IF 22.415). He hosted one National Key Funded Project, one National Natural Science Foundation Project, one Start-up Fund for Returned Overseas Students from the Ministry of Education, two Provincial Projects, and three Shenzhen Science and Technology Projects.

 

The 863 national key funded projects and general projects have focused on the introduction of a transmembrane peptide sequence at the amino terminus of the mimetic epitope peptide to enable the peptide to efficiently enter the DC cytoplasm, and an endoplasmic reticulum targeting at the carboxy terminus of the mimetic epitope peptide sequence to increase the efficiency of DC internalization of peptides, thereby improving the efficacy of peptide-loaded DC vaccines. The sponsored start-up fund of the Returned Overseas Students from the Ministry of Education described the role and molecular mechanism of autophagy in reversing tumor resistance by low-frequency ultrasound. This project discovered a looped pathway between autophagy and endoplasmic reticulum stress.

 

He was the first to carry out airless laparoscopic radical prostatectomy; the first to carry out complete retroperitoneal laparoscopic renal ureteral full length and bladder cuff resection and super-selective renal artery embolization after laparoscopic tumor removal. He also completed a pneumatic bladder laparoscopic partial cystectomy and invented the laparoscopic bladder neck dragging strategy in the context of prostate cancer radical resection. He won the first prize of Chongqing Science and Technology Progress Award in 2016.

 

B. Positions and honors

Positions

2012-2013  Visiting professor of Georgia Medical University, USA

2015-2017  Consultant Surgeon, The Second Affiliated Hospital of Third Military Medical University,China

2017-2020  Director of Urology, Shenzhen University General Hospital, Shenzhen, China

 

Honors

First prize of Chongqing Science and Technology Progress Award in 2016

 

C. Representative publications (selected publications in recent five years   5-10篇)

1.Wu YQ, Hu L, Qin ZZ, Wang XW#. MicroRNA-302a upregulation mediates chemo-resistance in prostate cancer cells. Molecular Medicine Reports. 2019;19(5):4433-40.

2.Wang XB, Wang X, Zhu ZY, Li WS, Yu GQ, Jia ZH, Wang XW#. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma. Biomedicine & Pharmacotherapy. 2019;117.

3.Lu KS, Xiao WW, Li SL, Liu XD, Wang H, Jiang JH, Wang XW#, Wang R, Zhu P. Analysis of drug resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae in children with urinary tract infection. Saudi Medical Journal. 2019;40(11):1111-5.

4.Zhu LL, Zou J, Zhao YY, Jiang XM, Wang Y, Wang XW, Chen B. ER-alpha 36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Journal of Experimental & Clinical Cancer Research. 2018;37.

5.Wu YQ, Liu XB, Qin ZZ, Hu L, Wang XW#. Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway. OncoTargets and Therapy. 2018;11:5621-30.

 

D. Research support

Ongoing projects (RMB)

1.Shenzhen Science and Technology Innovation Committee 2019 General Project

(JCYJ20190808141013454), 01/03/2020 to 01/03/2023, Xiangwei Wang, PI, RMB 300,000

 

2.Shenzhen Science and Technology Innovation Committee 2018 Basic Research Free Exploration Project (JCYJ20180305124827261),01/03/2019 to 01/03/2021, Xiangwei Wang, PI, RMB 500,000

 

3.Shenzhen Science and Technology Innovation Committee 2018 Basic Research Discipline Layout Project (JCYJ20180507182415428),01/03/2018 to 01/03/2022, Xiangwei Wang, PI, RMB 3,000,000

 

4.Shenzhen University General Hospital Technology Talent Promotion Program (SUGH2018QD025)01/04/2018 to 01/04/2020, Xiangwei Wang, PI, RMB 300,000